喘可治注射液多途径给药联合沙美特罗替卡松粉吸入剂治疗中重度慢性阻塞性肺疾病急性加重期的疗效评价  

Evaluation on Therapeutic Efficacy of Chuankezhi by Different Administration Pathways Combined with Salmeterol Rinafoate and Fluticasone Propionate Powder for Inhalation on Acute Exacerbation of Moderate-Severe COPD

作　　者：李梦 黄民强 何光辉 吕玉亮 LI Meng;HUANG Minqiang;HE Guanghui(Nanxiang Hospital of Shanghai Jiading District,Shanghai Jiading District 201802,China)

机构地区：[1]上海市嘉定区南翔医院呼吸内科,上海嘉定区201802

出　　处：《河北医学》2019年第2期189-193,共5页Hebei Medicine

基　　金：上海市嘉定区卫生和计划生育委员会中医药科研课题;(编号:2015-QN-ZYY-02)

摘　　要：目的:探讨喘可治注射液多途径给药联合沙美特罗替卡松粉吸入剂治疗中重度慢性阻塞性肺疾病急性加重期的疗效。方法:选取我院2016年1月至2018年4月就诊收治的90例中重度COPD急性加重期患者作为研究对象,随机分为治疗组和对照组,各45例。对照组给予沙美特罗替卡松粉吸入剂治疗,治疗组给予喘可治注射液多途径给药联沙美特罗替卡松粉吸入剂治疗。比较两组患者治疗前后的治疗疗效、不良反应发生情况及治疗前后的肺功能指标、血气指标、m MRC评分、CAT评分变化情况。结果:治疗组总有效率高于对照组,有统计学差异(88.89%vs71.11%,P<0.05);两组患者治疗后FEV1、FEV1/FVC、PEF及6min步行距离水平均高于治疗前(P<0.05),且治疗后治疗组FEV1、FEV1/FVC、PEF及6min步行距离水平高于对照组(P <0.05);两组患者治疗后PaCO_2均低于治疗前,PaO_2、SaO_2水平均高于治疗前(P<0.05),且治疗组治疗后PaCO_2低于对照组,PaO_2、SaO_2水平高于对照组(P<0.05);两组患者mMRC、CAT评分水平均低于治疗前(P<0.05),且治疗组m MRC、CAT评分水平均均低于对照组(P<0.05);两组患者不良反应总发生率比较无明显差异(8.88%vs6.66%,P>0.05)。结论:喘可治多途径给药联合沙美特罗替卡松粉吸入剂治疗中重度COPD急性加重期患者临床疗效显著,可有效改善其肺功能、血气指标,提高生活质量。Objective:To investigate therapeutic efficacy evaluation of chuankezhi injection by different administration pathways combined with salmeterol xinafoate and fluticasone propionate powder for inhalation in the treatment of acute exacerbation of moderate-severe chronic obstructive pulmonary disease(COPD).Methods:90 cases of moderate-severe COPD in acute exacerbation treated in our hospital from January 2016 to April 2018 were selected and equally divided into two groups.The control group received the salmeterol xinafoate and fluticasone propionate powder for inhalation,while the treatment group received the chuankezhi by different administration combined with salmeterol xinafoate and fluticasone propionate powder for inhalation.Then the clinical efficacy,adverse reactions,pulmonary function indicators,blood gas parameters,mMRC scores,and CAT scores of the two groups were compared.Results:The total clinical efficacy of the treatment group was higher than that of the control group,and the difference was statistically significant(88.89%vs 71.11%,P<0.05);The FEV1,FEV1/FVC,PEF and 6min walking distance of the two groups were increased after treatment,and were higher in the treatment group than those in the control group(P<0.05);The PaCO 2 of the two groups were decreased,while the PaO 2 and SaO 2 were increased after treatment(P<0.05);The treatment group had lower level of PaCO 2 as well as higher levels of PaO 2 and SaO 2 than those of the control group(P<0.05);The scores of mMRC and CAT of the two groups were decreased(P<0.05),and were lower in the treatment group than in the control group(P<0.05);The incidence rate of the adverse reactions of the two groups had no difference(8.88%vs 6.66%,P>0.05).Conclusion:Chuankezhi injection by different administration pathways combined with salmeterol xinafoate and fluticasone propionate powder for inhalation is an effective way to ameliorate the pulmonary function,blood indexes and quality of life for acute exacerbation of moderate-severe COPD.

关 键 词：喘可治注射液 沙美特罗替卡松粉吸入剂 中重度慢性阻塞性肺疾病 急性加重期 

分 类 号：R563.9[医药卫生—呼吸系统]